APO Research
Talk to an analyst

APO RESEARCH · REPORT

EGFR-TKI

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global EGFR-TKI Market Outlook and Growth Opportunities 2026

27 December 2025206 pages

Choose your research edition.

Industry ResearchEGFR-TKI Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal EGFR-TKI Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal EGFR-TKI Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal EGFR-TKI Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal EGFR-TKI Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global EGFR-TKI market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the EGFR-TKI market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the EGFR-TKI market include ArriVent Biopharma, AstraZeneca, Beacon Pharma, Boehringer Ingelheim Pharmaceuticals, Cipla, Drug International, Glenmark Pharmaceuticals, Hanmi Pharmaceutical and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global EGFR-TKI market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of EGFR-TKI and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents EGFR-TKI sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the EGFR-TKI market size, projected growth trends, production technologies, key applications, and end-use industries.

EGFR-TKI Segment by Company

ArriVent Biopharma

AstraZeneca

Beacon Pharma

Boehringer Ingelheim Pharmaceuticals

Cipla

Drug International

Glenmark Pharmaceuticals

Hanmi Pharmaceutical

Johnson & Johnson

Mylan

Pfizer

Roche

Teva

Yuhan Corporation

Betta Pharma

Chengdu Brilliant Pharmaceuticals

Hansoh Pharma

Shanghai Allist Pharmaceuticals

Wanbang Biopharmaceuticals

EGFR-TKI Segment by Type

Afatinib

Aumolertinib

Icotinib

Osimertinib

Dacomitinib

Erlotinib

Furmonertinib

Gefitinib

Lazertinib

Other

EGFR-TKI Segment by Application

Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

EGFR-TKI Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global EGFR-TKI status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions EGFR-TKI market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify EGFR-TKI significant trends, drivers, influence factors in global and regions.

6. To analyze EGFR-TKI competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global EGFR-TKI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of EGFR-TKI and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of EGFR-TKI.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the EGFR-TKI market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global EGFR-TKI industry.

Chapter 3: Detailed analysis of EGFR-TKI manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of EGFR-TKI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of EGFR-TKI in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. EGFR-TKI Industry Trends Table 2. EGFR-TKI Industry Drivers Table 3. EGFR-TKI Industry Opportunities and Challenges Table 4. EGFR-TKI Industry Restraints Table 5. Global EGFR-TKI Revenue by Company (US$ Million) & (2021-2026) Table 6. Global EGFR-TKI Revenue Share by Company (2021-2026) Table 7. Global EGFR-TKI Sales Volume by Company (K Units) & (2021-2026) Table 8. Global EGFR-TKI Sales Volume Share by Company (2021-2026) Table 9. Global EGFR-TKI Average Price (US$/Unit) of Company (2021-2026) Table 10. Global EGFR-TKI Company Ranking, (2024-2026) & (USD Million) Table 11. Global EGFR-TKI Key Company Manufacturing Base & Headquarters Table 12. Global EGFR-TKI Company, Product Type & Application Table 13. Global EGFR-TKI Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global EGFR-TKI by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Afatinib Table 18. Significant Companies of Aumolertinib Table 19. Significant Companies of Icotinib Table 20. Significant Companies of Osimertinib Table 21. Significant Companies of Dacomitinib Table 22. Significant Companies of Erlotinib Table 23. Significant Companies of Furmonertinib Table 24. Significant Companies of Gefitinib Table 25. Significant Companies of Lazertinib Table 26. Significant Companies of Other Table 27. Global EGFR-TKI Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global EGFR-TKI Sales Volume by Type (2021-2026) & (K Units) Table 29. Global EGFR-TKI Sales Volume by Type (2027-2032) & (K Units) Table 30. Global EGFR-TKI Sales Volume Share by Type (2021-2026) Table 31. Global EGFR-TKI Sales Volume Share by Type (2027-2032) Table 32. Global EGFR-TKI Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global EGFR-TKI Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global EGFR-TKI Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global EGFR-TKI Sales Value Share by Type (2021-2026) Table 36. Global EGFR-TKI Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Segment by Application Table 38. Significant Companies of Hospital and Clinic Table 39. Significant Companies of Retail Pharmacies Table 40. Significant Companies of Other Table 41. Global EGFR-TKI Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global EGFR-TKI Sales Volume by Application (2021-2026) & (K Units) Table 43. Global EGFR-TKI Sales Volume by Application (2027-2032) & (K Units) Table 44. Global EGFR-TKI Sales Volume Share by Application (2021-2026) Table 45. Global EGFR-TKI Sales Volume Share by Application (2027-2032) Table 46. Global EGFR-TKI Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global EGFR-TKI Sales Value by Application (2021-2026) & (US$ Million) Table 48. Global EGFR-TKI Sales Value by Application (2027-2032) & (US$ Million) Table 49. Global EGFR-TKI Sales Value Share by Application (2021-2026) Table 50. Global EGFR-TKI Sales Value Share by Application (2027-2032) Table 51. Global EGFR-TKI Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 52. Global EGFR-TKI Sales by Region (2021-2026) & (K Units) Table 53. Global EGFR-TKI Sales Market Share by Region (2021-2026) Table 54. Global EGFR-TKI Sales by Region (2027-2032) & (K Units) Table 55. Global EGFR-TKI Sales Market Share by Region (2027-2032) Table 56. Global EGFR-TKI Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global EGFR-TKI Sales Value by Region (2021-2026) & (US$ Million) Table 58. Global EGFR-TKI Sales Value Share by Region (2021-2026) Table 59. Global EGFR-TKI Sales Value by Region (2027-2032) & (US$ Million) Table 60. Global EGFR-TKI Sales Value Share by Region (2027-2032) Table 61. Global EGFR-TKI Market Average Price (US$/Unit) by Region (2021-2026) Table 62. Global EGFR-TKI Market Average Price (US$/Unit) by Region (2027-2032) Table 63. Global EGFR-TKI Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 64. Global EGFR-TKI Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global EGFR-TKI Sales by Country (2021-2026) & (K Units) Table 66. Global EGFR-TKI Sales Market Share by Country (2021-2026) Table 67. Global EGFR-TKI Sales by Country (2027-2032) & (K Units) Table 68. Global EGFR-TKI Sales Market Share by Country (2027-2032) Table 69. Global EGFR-TKI Sales Value by Country (2021-2026) & (US$ Million) Table 70. Global EGFR-TKI Sales Value Market Share by Country (2021-2026) Table 71. Global EGFR-TKI Sales Value by Country (2027-2032) & (US$ Million) Table 72. Global EGFR-TKI Sales Value Market Share by Country (2027-2032) Table 73. ArriVent Biopharma Company Information Table 74. ArriVent Biopharma Business Overview Table 75. ArriVent Biopharma EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. ArriVent Biopharma EGFR-TKI Product Portfolio Table 77. ArriVent Biopharma Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AstraZeneca EGFR-TKI Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Beacon Pharma Company Information Table 84. Beacon Pharma Business Overview Table 85. Beacon Pharma EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beacon Pharma EGFR-TKI Product Portfolio Table 87. Beacon Pharma Recent Development Table 88. Boehringer Ingelheim Pharmaceuticals Company Information Table 89. Boehringer Ingelheim Pharmaceuticals Business Overview Table 90. Boehringer Ingelheim Pharmaceuticals EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Boehringer Ingelheim Pharmaceuticals EGFR-TKI Product Portfolio Table 92. Boehringer Ingelheim Pharmaceuticals Recent Development Table 93. Cipla Company Information Table 94. Cipla Business Overview Table 95. Cipla EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cipla EGFR-TKI Product Portfolio Table 97. Cipla Recent Development Table 98. Drug International Company Information Table 99. Drug International Business Overview Table 100. Drug International EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Drug International EGFR-TKI Product Portfolio Table 102. Drug International Recent Development Table 103. Glenmark Pharmaceuticals Company Information Table 104. Glenmark Pharmaceuticals Business Overview Table 105. Glenmark Pharmaceuticals EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Glenmark Pharmaceuticals EGFR-TKI Product Portfolio Table 107. Glenmark Pharmaceuticals Recent Development Table 108. Hanmi Pharmaceutical Company Information Table 109. Hanmi Pharmaceutical Business Overview Table 110. Hanmi Pharmaceutical EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Hanmi Pharmaceutical EGFR-TKI Product Portfolio Table 112. Hanmi Pharmaceutical Recent Development Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson EGFR-TKI Product Portfolio Table 117. Johnson & Johnson Recent Development Table 118. Mylan Company Information Table 119. Mylan Business Overview Table 120. Mylan EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Mylan EGFR-TKI Product Portfolio Table 122. Mylan Recent Development Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Pfizer EGFR-TKI Product Portfolio Table 127. Pfizer Recent Development Table 128. Roche Company Information Table 129. Roche Business Overview Table 130. Roche EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Roche EGFR-TKI Product Portfolio Table 132. Roche Recent Development Table 133. Teva Company Information Table 134. Teva Business Overview Table 135. Teva EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Teva EGFR-TKI Product Portfolio Table 137. Teva Recent Development Table 138. Yuhan Corporation Company Information Table 139. Yuhan Corporation Business Overview Table 140. Yuhan Corporation EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Yuhan Corporation EGFR-TKI Product Portfolio Table 142. Yuhan Corporation Recent Development Table 143. Betta Pharma Company Information Table 144. Betta Pharma Business Overview Table 145. Betta Pharma EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Betta Pharma EGFR-TKI Product Portfolio Table 147. Betta Pharma Recent Development Table 148. Chengdu Brilliant Pharmaceuticals Company Information Table 149. Chengdu Brilliant Pharmaceuticals Business Overview Table 150. Chengdu Brilliant Pharmaceuticals EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Chengdu Brilliant Pharmaceuticals EGFR-TKI Product Portfolio Table 152. Chengdu Brilliant Pharmaceuticals Recent Development Table 153. Hansoh Pharma Company Information Table 154. Hansoh Pharma Business Overview Table 155. Hansoh Pharma EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Hansoh Pharma EGFR-TKI Product Portfolio Table 157. Hansoh Pharma Recent Development Table 158. Shanghai Allist Pharmaceuticals Company Information Table 159. Shanghai Allist Pharmaceuticals Business Overview Table 160. Shanghai Allist Pharmaceuticals EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Shanghai Allist Pharmaceuticals EGFR-TKI Product Portfolio Table 162. Shanghai Allist Pharmaceuticals Recent Development Table 163. Wanbang Biopharmaceuticals Company Information Table 164. Wanbang Biopharmaceuticals Business Overview Table 165. Wanbang Biopharmaceuticals EGFR-TKI Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Wanbang Biopharmaceuticals EGFR-TKI Product Portfolio Table 167. Wanbang Biopharmaceuticals Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. EGFR-TKI Distributors List Table 171. EGFR-TKI Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. EGFR-TKI Product Image Figure 2. Global EGFR-TKI Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 4. Global EGFR-TKI Sales (2021-2032) & (K Units) Figure 5. Global EGFR-TKI Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global EGFR-TKI Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Afatinib Image Figure 10. Aumolertinib Image Figure 11. Icotinib Image Figure 12. Osimertinib Image Figure 13. Dacomitinib Image Figure 14. Erlotinib Image Figure 15. Furmonertinib Image Figure 16. Gefitinib Image Figure 17. Lazertinib Image Figure 18. Other Image Figure 19. Global EGFR-TKI Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global EGFR-TKI Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global EGFR-TKI Sales Volume Share by Type (2021-2032) Figure 22. Global EGFR-TKI Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global EGFR-TKI Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global EGFR-TKI Sales Value Share by Type (2021-2032) Figure 25. Segment by Application Image Figure 26. Hospital and Clinic Image Figure 27. Retail Pharmacies Image Figure 28. Other Image Figure 29. Global EGFR-TKI Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global EGFR-TKI Sales Volume Share 2021 VS 2025 VS 2032 Figure 31. Global EGFR-TKI Sales Volume Share by Application (2021-2032) Figure 32. Global EGFR-TKI Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global EGFR-TKI Sales Value Share 2021 VS 2025 VS 2032 Figure 34. Global EGFR-TKI Sales Value Share by Application (2021-2032) Figure 35. Global EGFR-TKI Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 36. Global EGFR-TKI Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 37. Global EGFR-TKI Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 38. Global EGFR-TKI Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 39. North America EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 40. North America EGFR-TKI Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Europe EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 42. Europe EGFR-TKI Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Asia-Pacific EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 44. Asia-Pacific EGFR-TKI Sales Value Share by Country (%), 2025 VS 2032 Figure 45. South America EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 46. South America EGFR-TKI Sales Value Share by Country (%), 2025 VS 2032 Figure 47. Middle East & Africa EGFR-TKI Sales Value (2021-2032) & (US$ Million) Figure 48. Middle East & Africa EGFR-TKI Sales Value Share by Country (%), 2025 VS 2032 Figure 49. USA EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. USA EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. USA EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Canada EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Canada EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Canada EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Mexico EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Mexico EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Mexico EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Germany EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Germany EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Germany EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. France EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. France EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. France EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. U.K. EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. U.K. EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. U.K. EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Italy EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Italy EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Italy EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Spain EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Spain EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Spain EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Russia EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Russia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Russia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Netherlands EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Netherlands EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Netherlands EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Nordic Countries EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Nordic Countries EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Nordic Countries EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. China EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. China EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. China EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Japan EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Japan EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Japan EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. South Korea EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. South Korea EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. South Korea EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. India EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. India EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. India EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Australia EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Australia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Australia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Southeast Asia EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Southeast Asia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Southeast Asia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Brazil EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Brazil EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Brazil EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Argentina EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Argentina EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Argentina EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Chile EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Chile EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Chile EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Colombia EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Colombia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Colombia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Peru EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Peru EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Peru EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Saudi Arabia EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Saudi Arabia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Saudi Arabia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Israel EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Israel Arabia EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Israel Arabia EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. UAE EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. UAE EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. UAE EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Turkey EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Turkey EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Turkey EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Iran EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Iran EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Iran EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Egypt EGFR-TKI Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 131. Egypt EGFR-TKI Sales Value Share by Type, 2025 VS 2032 & (%) Figure 132. Egypt EGFR-TKI Sales Value Share by Application, 2025 VS 2032 & (%) Figure 133. EGFR-TKI Value Chain Figure 134. Manufacturing Cost Structure Figure 135. EGFR-TKI Sales Mode & Process Figure 136. Direct Comparison with Distribution Share Figure 137. Distributors Profiles Figure 138. Years Considered Figure 139. Research Process Figure 140. Key Executives Interviewed

Scope & coverage.

Types
  • Afatinib
  • Aumolertinib
  • Icotinib
  • Osimertinib
  • Dacomitinib
  • Erlotinib
  • Furmonertinib
  • Gefitinib
  • Lazertinib
  • Other
Applications
  • Segment by Application
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • ArriVent Biopharma
  • AstraZeneca
  • Beacon Pharma
  • Boehringer Ingelheim Pharmaceuticals
  • Cipla
  • Drug International
  • Glenmark Pharmaceuticals
  • Hanmi Pharmaceutical
  • Johnson & Johnson
  • Mylan
  • Pfizer
  • Roche
  • Teva
  • Yuhan Corporation
  • Betta Pharma
  • Chengdu Brilliant Pharmaceuticals
  • Hansoh Pharma
  • Shanghai Allist Pharmaceuticals
  • Wanbang Biopharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global EGFR-TKI Sales Value (2021-2032)
  4. 1.2.2 Global EGFR-TKI Sales Volume (2021-2032)
  5. 1.2.3 Global EGFR-TKI Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 EGFR-TKI Market Dynamics
  1. 2.1 EGFR-TKI Industry Trends
  2. 2.2 EGFR-TKI Industry Drivers
  3. 2.3 EGFR-TKI Industry Opportunities and Challenges
  4. 2.4 EGFR-TKI Industry Restraints
3 EGFR-TKI Market by Company
  1. 3.1 Global EGFR-TKI Company Revenue Ranking in 2025
  2. 3.2 Global EGFR-TKI Revenue by Company (2021-2026)
  3. 3.3 Global EGFR-TKI Sales Volume by Company (2021-2026)
  4. 3.4 Global EGFR-TKI Average Price by Company (2021-2026)
  5. 3.5 Global EGFR-TKI Company Ranking (2024-2026)
  6. 3.6 Global EGFR-TKI Company Manufacturing Base and Headquarters
  7. 3.7 Global EGFR-TKI Company Product Type and Application
  8. 3.8 Global EGFR-TKI Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global EGFR-TKI Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 EGFR-TKI Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 EGFR-TKI Market by Type
  1. 4.1 EGFR-TKI Type Introduction
  2. 4.1.1 Afatinib
  3. 4.1.2 Aumolertinib
  4. 4.1.3 Icotinib
  5. 4.1.4 Osimertinib
  6. 4.1.5 Dacomitinib
  7. 4.1.6 Erlotinib
  8. 4.1.7 Furmonertinib
  9. 4.1.8 Gefitinib
  10. 4.1.9 Lazertinib
  11. 4.1.10 Other
  12. 4.2 Global EGFR-TKI Sales Volume by Type
  13. 4.2.1 Global EGFR-TKI Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global EGFR-TKI Sales Volume by Type (2021-2032)
  15. 4.2.3 Global EGFR-TKI Sales Volume Share by Type (2021-2032)
  16. 4.3 Global EGFR-TKI Sales Value by Type
  17. 4.3.1 Global EGFR-TKI Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global EGFR-TKI Sales Value by Type (2021-2032)
  19. 4.3.3 Global EGFR-TKI Sales Value Share by Type (2021-2032)
5 EGFR-TKI Market by Application
  1. 5.1 EGFR-TKI Application Introduction
  2. 5.1.1 Segment by Application
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Retail Pharmacies
  5. 5.1.4 Other
  6. 5.2 Global EGFR-TKI Sales Volume by Application
  7. 5.2.1 Global EGFR-TKI Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global EGFR-TKI Sales Volume by Application (2021-2032)
  9. 5.2.3 Global EGFR-TKI Sales Volume Share by Application (2021-2032)
  10. 5.3 Global EGFR-TKI Sales Value by Application
  11. 5.3.1 Global EGFR-TKI Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global EGFR-TKI Sales Value by Application (2021-2032)
  13. 5.3.3 Global EGFR-TKI Sales Value Share by Application (2021-2032)
6 EGFR-TKI Regional Sales and Value Analysis
  1. 6.1 Global EGFR-TKI Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global EGFR-TKI Sales by Region (2021-2032)
  3. 6.2.1 Global EGFR-TKI Sales by Region: 2021-2026
  4. 6.2.2 Global EGFR-TKI Sales by Region (2027-2032)
  5. 6.3 Global EGFR-TKI Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global EGFR-TKI Sales Value by Region (2021-2032)
  7. 6.4.1 Global EGFR-TKI Sales Value by Region: 2021-2026
  8. 6.4.2 Global EGFR-TKI Sales Value by Region (2027-2032)
  9. 6.5 Global EGFR-TKI Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America EGFR-TKI Sales Value (2021-2032)
  12. 6.6.2 North America EGFR-TKI Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe EGFR-TKI Sales Value (2021-2032)
  15. 6.7.2 Europe EGFR-TKI Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific EGFR-TKI Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific EGFR-TKI Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America EGFR-TKI Sales Value (2021-2032)
  21. 6.9.2 South America EGFR-TKI Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa EGFR-TKI Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa EGFR-TKI Sales Value Share by Country, 2025 VS 2032
7 EGFR-TKI Country-level Sales and Value Analysis
  1. 7.1 Global EGFR-TKI Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global EGFR-TKI Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global EGFR-TKI Sales by Country (2021-2032)
  4. 7.3.1 Global EGFR-TKI Sales by Country (2021-2026)
  5. 7.3.2 Global EGFR-TKI Sales by Country (2027-2032)
  6. 7.4 Global EGFR-TKI Sales Value by Country (2021-2032)
  7. 7.4.1 Global EGFR-TKI Sales Value by Country (2021-2026)
  8. 7.4.2 Global EGFR-TKI Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA EGFR-TKI Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada EGFR-TKI Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico EGFR-TKI Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany EGFR-TKI Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France EGFR-TKI Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. EGFR-TKI Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy EGFR-TKI Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain EGFR-TKI Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia EGFR-TKI Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands EGFR-TKI Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries EGFR-TKI Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China EGFR-TKI Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan EGFR-TKI Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea EGFR-TKI Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India EGFR-TKI Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia EGFR-TKI Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia EGFR-TKI Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil EGFR-TKI Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina EGFR-TKI Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile EGFR-TKI Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia EGFR-TKI Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru EGFR-TKI Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia EGFR-TKI Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel EGFR-TKI Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE EGFR-TKI Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey EGFR-TKI Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran EGFR-TKI Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran EGFR-TKI Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt EGFR-TKI Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt EGFR-TKI Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt EGFR-TKI Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ArriVent Biopharma
  2. 8.1.1 ArriVent Biopharma Company Information
  3. 8.1.2 ArriVent Biopharma Business Overview
  4. 8.1.3 ArriVent Biopharma EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ArriVent Biopharma EGFR-TKI Product Portfolio
  6. 8.1.5 ArriVent Biopharma Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca EGFR-TKI Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Beacon Pharma
  14. 8.3.1 Beacon Pharma Company Information
  15. 8.3.2 Beacon Pharma Business Overview
  16. 8.3.3 Beacon Pharma EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Beacon Pharma EGFR-TKI Product Portfolio
  18. 8.3.5 Beacon Pharma Recent Developments
  19. 8.4 Boehringer Ingelheim Pharmaceuticals
  20. 8.4.1 Boehringer Ingelheim Pharmaceuticals Company Information
  21. 8.4.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  22. 8.4.3 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  25. 8.5 Cipla
  26. 8.5.1 Cipla Company Information
  27. 8.5.2 Cipla Business Overview
  28. 8.5.3 Cipla EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cipla EGFR-TKI Product Portfolio
  30. 8.5.5 Cipla Recent Developments
  31. 8.6 Drug International
  32. 8.6.1 Drug International Company Information
  33. 8.6.2 Drug International Business Overview
  34. 8.6.3 Drug International EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Drug International EGFR-TKI Product Portfolio
  36. 8.6.5 Drug International Recent Developments
  37. 8.7 Glenmark Pharmaceuticals
  38. 8.7.1 Glenmark Pharmaceuticals Company Information
  39. 8.7.2 Glenmark Pharmaceuticals Business Overview
  40. 8.7.3 Glenmark Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark Pharmaceuticals EGFR-TKI Product Portfolio
  42. 8.7.5 Glenmark Pharmaceuticals Recent Developments
  43. 8.8 Hanmi Pharmaceutical
  44. 8.8.1 Hanmi Pharmaceutical Company Information
  45. 8.8.2 Hanmi Pharmaceutical Business Overview
  46. 8.8.3 Hanmi Pharmaceutical EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hanmi Pharmaceutical EGFR-TKI Product Portfolio
  48. 8.8.5 Hanmi Pharmaceutical Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson EGFR-TKI Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mylan EGFR-TKI Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer EGFR-TKI Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Roche EGFR-TKI Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Teva EGFR-TKI Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Yuhan Corporation
  80. 8.14.1 Yuhan Corporation Company Information
  81. 8.14.2 Yuhan Corporation Business Overview
  82. 8.14.3 Yuhan Corporation EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Yuhan Corporation EGFR-TKI Product Portfolio
  84. 8.14.5 Yuhan Corporation Recent Developments
  85. 8.15 Betta Pharma
  86. 8.15.1 Betta Pharma Company Information
  87. 8.15.2 Betta Pharma Business Overview
  88. 8.15.3 Betta Pharma EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Betta Pharma EGFR-TKI Product Portfolio
  90. 8.15.5 Betta Pharma Recent Developments
  91. 8.16 Chengdu Brilliant Pharmaceuticals
  92. 8.16.1 Chengdu Brilliant Pharmaceuticals Company Information
  93. 8.16.2 Chengdu Brilliant Pharmaceuticals Business Overview
  94. 8.16.3 Chengdu Brilliant Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Chengdu Brilliant Pharmaceuticals EGFR-TKI Product Portfolio
  96. 8.16.5 Chengdu Brilliant Pharmaceuticals Recent Developments
  97. 8.17 Hansoh Pharma
  98. 8.17.1 Hansoh Pharma Company Information
  99. 8.17.2 Hansoh Pharma Business Overview
  100. 8.17.3 Hansoh Pharma EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Hansoh Pharma EGFR-TKI Product Portfolio
  102. 8.17.5 Hansoh Pharma Recent Developments
  103. 8.18 Shanghai Allist Pharmaceuticals
  104. 8.18.1 Shanghai Allist Pharmaceuticals Company Information
  105. 8.18.2 Shanghai Allist Pharmaceuticals Business Overview
  106. 8.18.3 Shanghai Allist Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Shanghai Allist Pharmaceuticals EGFR-TKI Product Portfolio
  108. 8.18.5 Shanghai Allist Pharmaceuticals Recent Developments
  109. 8.19 Wanbang Biopharmaceuticals
  110. 8.19.1 Wanbang Biopharmaceuticals Company Information
  111. 8.19.2 Wanbang Biopharmaceuticals Business Overview
  112. 8.19.3 Wanbang Biopharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Wanbang Biopharmaceuticals EGFR-TKI Product Portfolio
  114. 8.19.5 Wanbang Biopharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 EGFR-TKI Value Chain Analysis
  2. 9.1.1 EGFR-TKI Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 EGFR-TKI Sales Mode & Process
  6. 9.2 EGFR-TKI Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 EGFR-TKI Distributors
  9. 9.2.3 EGFR-TKI Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst